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Poster Session I 83days post SCT. In summary, NAC and AlloSCT in patients with
SCD using both related and unrelated donors has been shown to
be well tolerated and effective in inducing a high degree of mixed
donor chimerism.222
DONOR CHIMERISM KINETICS IN PEDIATRIC PATIENTS UNDERGOING
REDUCED INTENSITY CONDITIONING (RIC) WITH ALLOGENEIC HEMA-
TOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
Schneiderman, J.1, Rademaker, A.W.2, Chaudry, S.1, Tse, W.1,
Jacobsohn, D.A.1, Duerst, R.1, Kletzel, M.1. 1Children’s Memorial Hos-
pital, Northwestern University Fienberg School of Medicine, Chicago, IL;
2Northwestern University Feinberg School of Medicine, Chicago, IL.
From 9/03–9/07 fifty-three children with malignant (n5 31) and
non-malignant diseases (immune deficiencies, metabolic disorders,
severe aplastic anemia, n5 22) underwent RIC HSCT; median age
at time of HSCT was 8 years (1 month - 17 years). RIC included flu-
darabine 30 mg/m2/d  5 d and targeted (AUC 4000 micorMol*-
min) single daily IV busulfanX2d (n 5 4), 1 ATG(n 5 34) or 2
weekly treatments of extracorporeal photopheresis (ECP, n 5 12).
Three received other fludarabine-based regimens. GVHD prophy-
laxis included CSA6MMF (n5 53),1 post-HSCT ECP (n5 12).
Neutrophil and platelet recovery were defined as 1st of three con-
secutive ANC . 500/ml and platelet count . 20,000/ml without
transfusion. Lineage specific chimerism assays of total white
cells(TW), T-cell (CD3), and myeloid cells (CD33) were moni-
tored serially post-HSCT by variable number tandem re-
peats(VNTR) assays. Full donor chimerism (FDC) was defined
as$95 1 5%, subsequent loss of full donor chimerism was defined
as a drop below 50%. Patients who did not reach 95% were termed
mixed chimerism. Neutrophil recovery occured in 94% at a median
of 18 days (4–39); one never fell below 500/ml. Platelet recovery was
evaluated in 52; 54% did not fall below 20,000/ l, 40% reached
20,000/ml (median 20 days, 9 – 158), and 38% reached 50,000/ml
(median 20.5 days, 11–142). Median cell doses per kilogram body
weight were as follows: CD34 6.77  106 (0.12 – 25.8), MNC
4.84 108 (0.27 – 8.85), and TNC 8.15 108 (0.41 – 46.1). No cor-
relation between cell dose and neutrophil recovery was seen; signif-
icant correlation was seen between cell dose and platelet recovery
(CD34, p 5 0.009, MNC, p 5 0.05, TNC, p 5 0.02). Patients
who received RIC HSCT (Table 1) for malignant disorders when
compared with non-malignant disorders showed a significant differ-
ence in achieving FDC in TW (p 5 0.0002) and myeloid (p 5
0.0002) cell lines. Two lost TW chimerism (malignant n 5 1, day
46, non-malignant n 5 1, day 340). 17/53 achieved mixed chime-
rism (malignant n 5 4, non-malignant n 5 13); those with malig-
nant disease received second HSCT. Non-malignant patients
remain free of disease (2nd HSCT n 5 7). There is significant dif-
ference in achieving FDC in those pts with malignancies which may
be attributed to prior therapy. Stable partial chimerism may be suf-
ficient in pts with non-malignant diseases. Chimerism requires fre-
quent monitoring; interventions such as changing immune
suppression or donor lymphocyte infusions must be considered.Table 1.
Median MedianRIC With
Allo-HSCTFDC
TW (%)Median
Time to FDC
TW (days)FDC
T-cell (%)Time to
FDC T-cell
(days)FDC
Myeloid
Cell (%)Time to
FDC Myeloid
(days)All Patients
(n 5 53)68% 48 69% 99 75% 29Malignant
Diseases
(n 5 31)87% 33 82% 97 85% 26Non-Malignant
Diseases
(n 5 22)41% 383 52% 169 48% 167p 5 0.0002 p 5 0.1 p 5 0.0002223
ALTERNATIVE DONOR HEMATOPOIETIC STEM CELL TRANSPLANTA-
TION FOR PEDIATRIC PATIENTS WITH ACUTE LYMPHOBLASTIC LEUKE-
MIA USING CAMPATH IN A MYELOABLATIVE CONDITIONING REGIMEN
Kennedy-Nasser, A.A., Myers, G.D., Leung, K.S., Gottschalk, S.,
Bollard, C.M., Heslop, H.E., Brenner,M.K., Krance, R.A. Baylor College
ofMedicine, Texas Children’s Hospital, TheMethodist Hospital, Houston,
TX.
Allogeneic transplantation from a matched sibling donor (MSD)
offers curative therapy for pediatric patients with acute lymphoblas-
tic leukemia (ALL); however, less than 30% of patients will have
a MSD. Alternative donor (AD) transplantation is a viable option
for these patients, but the risk for GVHD remains much higher.
From 2001 to present, we have used Campath in the conditioning
regimen for AD transplants to achieve in vivo T-cell depletion, in
an effort to reduce the risk of GVHD. Here we report the outcome
of pediatric ALL patients receiving AD transplants using Campath
as part of a myeloablative conditioning regimen. Risk assessment is
assigned prior to transplant – standard risk (SR) includes patients
with ALL in 1st or 2nd complete remission. Since 1997, 39 patients
with SR ALL were transplanted with MSD grafts, and since institut-
ing Campath in 2001, 39 patients have received AD grafts. AD pa-
tients received bone marrow or peripheral blood stem cell products
from up to 1 antigen mismatched related or unrelated donor. Mye-
loablative conditioning included cyclophosphamide, cytarabine
arabinoside and total body irradiation (1200 cGy for MSD and
1400 cGy for AD) in all patients with the addition of Campath in
the AD recipients. Additional GVHD prophylaxis consisted of
FK506 or cyclosporine with either methotrexate or prednisone.
All but one evaluable patient achieved neutrophil engraftment.
The 5-year disease-free survival for patients with MSD was 83%
compared to 60% for AD recipients. The 100-day mortality was
8% in the AD group and 3% in the MSD group. GVHD was low
in the AD cohort – 13% developed grade II-IV acute GVHD and
none developed extensive, chronic GVHD. Consistent with other
published reports using Campath, we did observe a high incidence
of viral infections – 28% developed adenovirus reactivation; 28%
developed CMV reactivation; and 3% developed EBV-LPD. We
conclude that Campath used with a myeloablative conditioning reg-
imen offers a curative option for pediatric patients with acute lym-
phoblastic leukemia requiring alternative donor transplantation
with a low incidence of GVHD.224
OUTCOMES OF UNRELATED UMBILICAL CORD BLOOD TRANSPLANTA-
TION IN PEDIATRIC PATIENTS WITH MYELODYSPLASTIC SYNDROME
Parikh, S.H.1, Mendizabal, A.2, Martin, P.L.1, Szabolcs, P.1,
Prasad, V.K.1, Driscoll, T.A.1, Kurtzberg, J.1. 1Duke UniversityMedical
Center, Durham, NC; 2The EMMES Corporation, Rockville, MD.
Between 1995 and 2007, 24 pediatric patients were transplanted
with unrelated donor umbilical cord blood (UCB). M:F ratio was
1.4; the median age was 10.5 years (range 1.11–19.73). Median
time from diagnosis to transplant was 6.43 months (range 2.00–
61.37). Patients were followed for a median time of 5.68 years (range
0.45–11.57). Eighty percent had primary disease. MDS stage was
RA/RC 12 pts, RAEB 8 pts and RAEB-T 4 pts. Monosomy-7 was
present in 18 (75%) patients. Patients with frank AML were ex-
cluded. Preparative regimen was TBI based in 19 (79%) patients
while Melphalan was used in 14 (58%) patients. GVHD prophylaxis
consisted of CSA/steroids (19 pts) and CSA/mycophenolate (5 pts).
Grafts were selected for matching at HLA Class I (A and B) at low
resolution and HLA Class II (DRB1) at the allelic level resulting in
17 (71%) 4/6 and 7 (29%) 5/6 matched transplants. The grafts con-
tained a median of 4.22  107 (range 1.68–12.58) total nucleated
cells (TNC)/kg pre-cryopreservation; 3.58  107 (range 1.01–
12.00) TNC/kg and 1.71 105/kg (range 0.17–28.46) CD341 cells
were infused. Cumulative incidence of neutrophil engraftment
(ANC . 500/mL) at Day 42 and Day 100 was 70.8% (95% CI
51.8%-89.8%) and 92.7% (95% CI 75.5%-100.0%), respectively,
and that of platelet engraftment (50K) at 180 days was 66.7%
(46.9%-86.5%). Three pts had graft failure while 4 pts (16%)
84 Poster Session Iengrafted slowly, after Day 42, perhaps related to some underlying
marrow dysfunction caused by MDS. Four patients developed acute
GvHD grades II-IV with a cumulative incidence at 100 Days of
16.7% (95% CI 1.4%-32.0%). Four patients relapsed with a CI of
relapse at 3 years of 15.0% (95% CI 0.0%-31.5%). Cumulative in-
cidence of non-relapse mortality at 1 year was 26.1% (95% CI
7.7%-44.5%). Nine pts died: 4 of infections (2 EBV, 1 adenovirus,
1 toxoplasmosis), 2 of graft failure, 2 of relapse, and 1 of MSOF.
Overall survival probability at 1 and 3 years were 70.4% (95% CI
51.9%-88.8%) and 59.5% (95% CI 38.7%-80.4%) respectively.
Event-free survival (EFS) probabilities at 1 and 3 years were
70.8% (95% CI 52.6%-89.0%) and 59.9% (39.2%-80.7%), respec-
tively. Factors associated with better EFS were age# 10 years (p5
0.03) and weight # 38 kg (p 5 0.02). These results, especially in
younger patients with Monosomy 7 and MDS, are equivalent to
matched allogeneic bone marrow transplant data. UCB should be
actively considered for pediatric MDS patients lacking matched re-
lated or unrelated adult donors.225
THE ADDITION OF ETOPOSIDE TO Bu16/Cy200 IN THE CONDITIONING
OF CHILDREN WITH ACUTE MYELOID LEUKEMIA (AML) UNDERGOING
ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) IS ASSOCIATED
WITH IMPROVED SURVIVAL
Ayas, M.1, Al-Mahr, M.1, Al-Jefri, A.1, Al-Seraihi, A.1, Belgaumi, A.1,
Al-Ahmari, A.1, El-Hassan, I.2, El-Solh, H.1. 1King Faisal Specialist
Hospital & Research Center, Riyadh, Saudi Arabia; 2King Faisal Special-
ist Hospital & Research Center, Riyadh, Saudi Arabia.
Relapse remains the major concern for children with AML un-
dergoing SCT, and we have previously shown that intensifying
the conditioning by adding etoposide at 60 mg/kg and consequently
reducing the busulfan (Bu) dose to 12 mg/kg and the cytoxan (Cy) to
90 mg/kg did not result in any significant improvement of the sur-
vival; we suggested then that the reduction of Bu/Cy doses necessi-
tated by addition of the high dose of etoposide could have affected
the outcome and we hypothesized that adding a lower dose of eto-
poside and keeping the Bu/Cy at the conventional doses may offer
better survival to AML patients undergoing allogeneic SCT. We
present here our results using such a protocol.
Patients andMethods: From March 2003 until December 2006,
33 patients with AML (24 in CR1, 8 in CR 2) underwent allogeneic
SCT and were conditioned with Bu 16 mg/kg po, Cy 200 mg/kg iv
plus etoposide 900 mg/m2 iv, median age was 9.6 years. This cohort
of patients (group B) was compared with 18 AML patients (17 in CR
1, 1 in CR 2) who underwent SCT from July 93 thru February 96,
median age at SCT was 7.25 years, patients were conditioned with
only Bu 16 mg/kg po and Cy 200 mg/kg iv (group A). Results: Me-
dian days to ANC$ 500  106/l was 21 days and 15 days in groups
A and B respectively, median days to platelet count$ 20 109/l was
22 days and 26 days in groups A and B respectively (P5 NS). The
incidence of complications was similar, acute GVHD grade 2 or
higher developed in 5% and 9% in groups A and B respectively
(P5 NS), hemorrhagic cystitis developed in 11% and 15% in
groups A and B respectively, no VOD developed in either group.
The 4 year overall survival for groups A and B respectively was
50% and 68.2% (P 5 0.3) and the 4 year event-free survival for
groups A and B respectively was 33% and 68.2% (P5 0.1).Conclu-
sions: The addition of etoposide to Bu16/Cy200 was not associated
with increased toxicity, and although it did not reach statistical sig-
nificance, it does appear to be associated with a better overall and
event-free survival. Larger scale studies are advised to further cor-
roborate our findings.226
SINGLE DAILY DOSE (SDD) BUSULFAN (BU) IN CHILDREN: COMPARI-
SON OF PHARMACOKINETICS (PK) AND ENGRAFTMENT BETWEEN
ACUTE LEUKAEMIA (AL) AND NON MALIGNANT DISEASE (NM)
Shaw, P.J.1,3, Nath, C.E.2, Earl, J.W.2. 1Children’s Hospital at West-
mead, Sydney, NSW, Australia; 2Children’s Hospital at Westmead, Syd-
ney, NSW, Australia; 3University of Sydney, Sydney, NSW, Australia.Methods: We studied BU PK, engraftment and survival in chil-
dren who underwent allogenic BMT for NM (n 5 33) or AL (n 5
41) after BU-based conditioning. The dose of oral BU was 4 mg/kg
(n5 16) or 150 mg/m2 (n 5 32) and intravenous (IV) 3.2 mg/kg (n
5 3), 120 mg/m2 (n5 3) or 130 mg/m2 (n5 20). In 62 cases, blood
was collected after the first dose, BU levels were measured and BU
area-under-the-concentration-versus-time curve (AUC) was deter-
mined using the Kinetica software (Innaphase, USA), then normal-
ized to 130 mg/m2 for IV BU and 150 mg/m2 for oral BU. PK-
guided dose adjustments were made in 7 patients with NM. Total
exposure to BU was determined by dividing first dose AUC by first
dose (mg) and then multiplying by the total dose (mg) administered.
Results: In the NM group, 26(79%) are still alive. 5 (of 7) deaths
occurred early (\118 d post BMT) due to transplant-related causes:
VOD (1), VOD and GVHD (2), GVHD (1) and sepsis (1). Full en-
graftment was achieved in all but 5 patients (85%): 2 had stable
mixed chimerism (MC) .95% donor, 3 had inadequate engraft-
ment; 4 of these were part of a group of 12 who had T cell depletion.
Total Bu exposure ranged from 57 to 146 mg/L.h (median 90 mg/
L.h). In the AL group, 29 (71%) are still alive, with 4 early trans-
plant-related deaths from GVHD (2), relapse (1) and sepsis (1).
Full engraftment was achieved in all but 3 patients (93%): 2 children
had MC and one of these subsequently lost the graft, another was
fully donor but died prior to obtaining full haematological recovery.
Total Bu exposure ranged from 40 to 345 mg/L.h (median 99 mg/
L.h). Results of the normalised AUC (nAUC) in mg/L.h are shown
in the table. nAUC was significantly higher in the oral BU group (n
5 36) than in the IV BU group (n5 26): 276 6 mg/L.h versus 236
8 mg/L.h, p\0.01. Conclusions: Single daily dose BU is generally
safe and effective for use in children with AL and NM. A dose of 130
mg/m2 IV gives less exposure than 150 mg/m2 oral. Wide variability
in BU pharmacokinetics indicates a need for measurement and per-
haps targeting in some patients, especially those with immune defi-
ciencies or those more likely to reject.normalised AUC (nAUC) mg/L.h
Diagnosis: Genetic SCID non-SCID ALIV Bu
nAUC (range) 20–44 14–50 18–31 14–30
median 23 16 21 18
fold variation 2.2 3.6 1.9 2.2
n 6 3 7 10Oral Bu
nAUC (range) 15–38 18–25 27–36 15–43
median 25 25 30 28
fold variation 2.5 1.4 1.3 2.9
n 9 3 4 20227
FUNGAL INFECTIONS: A SURVEY OF PEDIATRIC SURVEY OF PEDIATRIC
BLOOD & MARROW TRANSPLANT CONSORTIUM INSTITUTIONS
Fisher, V.L.1, Olson, E.A.2. 1Rainbow Babies & Children’s Hospital,
Cleveland, OH; 2Children’s Healthcare of Atlanta, Atlanta, GA.
This survey was designed to identify the fungal infection manage-
ment used for the pediatric BMT patient and to develop a standard
of care for fungal infection management by institutions within the
Pediatric Blood & Marrow Transplant Consortium (PBMTC).
Twenty five percent of the surveys were returned. 100% of the in-
stitutions performed allogeneic and autologous transplants. Non-
myeloablative transplants were performed by 89% of the institu-
tions.
All institutions used some type of fungal prophylaxis during
transplant, 77% used fungal prophylaxis on all their transplant pa-
tients. 50% of the centers differed on the prophylaxis used in the
BMT sub-groups, with 85% of the centers using Fluconazole,
and 15% of the institutions using no prophylaxis in autologous pa-
tients. 100% of centers administered prophylaxis to the allogeneic
transplant group. The break down of agents utilized in the allo-graft
group was Fluconazole (47%), Voriconazole (23%) and low dose
